The Long Noncoding RNA HOXA11 Antisense Induces Tumor Progression and Stemness Maintenance in Cervical Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Oct 30

PMID 27792998

Citations 45

Authors

Hee Jung Kim

Kyung Jin Eoh

Lee Kyung Kim

Eun Ji Nam

Sun Och Yoon

Kun-Hong Kim

Jae Kwan Lee

Sang Wun Kim

Young Tae Kim

Affiliations

Soon will be listed here.

Abstract

Recent research has focused on the impact of long noncoding RNA (lncRNA) in cervical carcinogenesis. However, whether HOXA11 antisense (HOXA11-AS) is involved in cervical cancer remains to be elucidated. In the present study, we examined HOXA11-AS expression levels in cervical cancer patients and determined the relationships between HOXA11-AS expression and clinicopathological factors. We also investigated the bio-functional consequences of HOXA11-AS overexpression both in vitro and in vivo. HOXA11-AS expression was significantly greater in tissues from patients with cervical cancer than in control patients (P<0.001). Multivariate analysis showed that high HOXA11-AS was an independent prognosticator of overall survival (Hazard ratio=2.450, P=0.032). HOXA11-AS overexpression enhanced cell proliferation, migration, and tumor invasion in vitro, whereas HOXA11-AS knockdown inhibited these biologic aggressive features. These adverse changes were accompanied by characteristics of epithelial-mesenchymal transition (EMT). In vivo xenograft experiments using the siHOXA11-AS-transfected HeLa cells revealed that HOXA11-AS strongly induced tumor growth. Furthermore, we found that HOXA11-AS knockdown decreased cancer stemness and triggered the EMT program. In conclusion, HOXA11-AS overexpression correlated with poor survival in patients with cervical cancer. Thus, HOXA11-AS may be a pivotal target for exploring novel cervical cancer therapeutics.

Citing Articles

Down-regulation of long noncoding RNA HOXA11-AS nullifies the impact of microRNA-506-3p on chondrocytes proliferation and apoptosis in osteoarthritis.

Zhang Z, Guo R, Cai C, Guo P Clinics (Sao Paulo). 2024; 79:100393.

PMID: 38815540 PMC: 11177079. DOI: 10.1016/j.clinsp.2024.100393.

Hypoxia/inflammation-induced upregulation of HIF-1α and C/EBPβ promotes nephroblastoma cell EMT by improving HOXA11-AS transcription.

Zhu S, Zhou R, Tang X, Fu W, Jia W Heliyon. 2024; 10(6):e27654.

PMID: 38524550 PMC: 10958367. DOI: 10.1016/j.heliyon.2024.e27654.

Targeting HOXA11-AS to mitigate prostate cancer via the glycolytic metabolism: In vitro and in vivo.

Zhang J, Li S, Zhang M, Wang Z, Xing Z J Cell Mol Med. 2024; 28(8):e18227.

PMID: 38520207 PMC: 10960170. DOI: 10.1111/jcmm.18227.

Long non-coding RNAs modulate tumor microenvironment to promote metastasis: novel avenue for therapeutic intervention.

Baba S, Baba S, Mir R, Elfaki I, Algehainy N, Ullah M Front Cell Dev Biol. 2023; 11:1164301.

PMID: 37384249 PMC: 10299194. DOI: 10.3389/fcell.2023.1164301.

HOXA‑AS3 induces tumor progression through the epithelial‑mesenchymal transition pathway in epithelial ovarian cancer.

Eoh K, Lee D, Nam E, In Kim J, Moon H, Kim S Oncol Rep. 2023; 49(3).

PMID: 36799173 PMC: 9944947. DOI: 10.3892/or.2023.8501.

References

Ferrand A, Sandrin M, Shulkes A, Baldwin G . Expression of gastrin precursors by CD133-positive colorectal cancer cells is crucial for tumour growth. Biochim Biophys Acta. 2009; 1793(3):477-88. PMC: 2692632. DOI: 10.1016/j.bbamcr.2009.01.004. View

Perez D, Hoage T, Pritchett J, Ducharme-Smith A, Halling M, Ganapathiraju S . Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet. 2007; 17(5):642-55. DOI: 10.1093/hmg/ddm336. View

Carninci P, Kasukawa T, Katayama S, Gough J, Frith M, Maeda N . The transcriptional landscape of the mammalian genome. Science. 2005; 309(5740):1559-63. DOI: 10.1126/science.1112014. View

Liu X, Yang W, Xu R, Liu J, Zheng P . Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells. PLoS One. 2014; 9(1):e87092. PMC: 3904967. DOI: 10.1371/journal.pone.0087092. View

Kim H, Lee D, Yim G, Nam E, Kim S, Kim S . Long non-coding RNA HOTAIR is associated with human cervical cancer progression. Int J Oncol. 2014; 46(2):521-30. PMC: 4277242. DOI: 10.3892/ijo.2014.2758. View

Curran S, Murray G . Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000; 36(13 Spec No):1621-30. DOI: 10.1016/s0959-8049(00)00156-8. View

Mainguy G, Koster J, Woltering J, Jansen H, Durston A . Extensive polycistronism and antisense transcription in the mammalian Hox clusters. PLoS One. 2007; 2(4):e356. PMC: 1831499. DOI: 10.1371/journal.pone.0000356. View

Noordhuis M, Fehrmann R, Wisman G, Nijhuis E, van Zanden J, Moerland P . Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011; 17(6):1317-30. DOI: 10.1158/1078-0432.CCR-10-2320. View

Wang Q, Zhang J, Liu Y, Zhang W, Zhou J, Duan R . A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett. 2016; 373(2):251-9. DOI: 10.1016/j.canlet.2016.01.039. View

10.

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

11.

Liu C, Xin Y, Tong C, Li B, Bao H, Zhang C . Production of interleukin‑4 in CD133+ cervical cancer stem cells promotes resistance to apoptosis and initiates tumor growth. Mol Med Rep. 2016; 13(6):5068-76. PMC: 4878543. DOI: 10.3892/mmr.2016.5195. View

12.

Chau Y, Pando S, Taylor H . HOXA11 silencing and endogenous HOXA11 antisense ribonucleic acid in the uterine endometrium. J Clin Endocrinol Metab. 2002; 87(6):2674-80. DOI: 10.1210/jcem.87.6.8527. View

13.

Krumlauf R . Hox genes in vertebrate development. Cell. 1994; 78(2):191-201. DOI: 10.1016/0092-8674(94)90290-9. View

14.

Biewenga P, van der Velden J, Mol B, Stalpers L, Schilthuis M, van der Steeg J . Prognostic model for survival in patients with early stage cervical cancer. Cancer. 2010; 117(4):768-76. DOI: 10.1002/cncr.25658. View

15.

Guttman M, Donaghey J, Carey B, Garber M, Grenier J, Munson G . lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011; 477(7364):295-300. PMC: 3175327. DOI: 10.1038/nature10398. View

16.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

17.

Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs I . HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer. 2008; 123(3):725-9. DOI: 10.1002/ijc.23563. View

18.

Apostolidou S, Hadwin R, Burnell M, Jones A, Baff D, Pyndiah N . DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer. 2009; 125(12):2995-3002. DOI: 10.1002/ijc.24745. View

19.

Burger R . Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. J Gynecol Oncol. 2010; 21(1):3-11. PMC: 2849946. DOI: 10.3802/jgo.2010.21.1.3. View

20.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View